002019.SHE Yifan Xinfu Pharmaceutical Co Ltd
- Market cap
- CNY 11.4B
- P/E
- 36.0x
- P/B
- 1.26x
- ROE
- 4.5%
- Dividend yield
- 1.51%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002019.SHE undervalued?
Graham number002019.SHE trades 42.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Yifan Xinfu Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Yifan Xinfu Pharmaceutical Co Ltd yet.
Yifan Xinfu Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Yifan Xinfu Pharmaceutical Co Ltd
Yifan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products, vitamins, and polymer materials in China, South Korea, the Philippines, Vietnam, Italy, Thailand, and internationally. It offers pharmaceutical products, such as biopharmaceuticals, chemical drugs, and traditional Chinese medicines; vitamin products, including vitamin B5 and provitamin B5; and active pharmaceutical ingredients. The company was formerly known …
Full company profileYifan Xinfu Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Yifan Xinfu Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.50B | 4.37B | 4.63B | 5.19B | 5.40B | 4.41B | 3.84B | 4.07B | 5.16B | 5.13B | 4.96B |
| Gross Profit | 1.77B | 2.50B | 2.04B | 2.38B | 2.50B | 1.81B | 1.85B | 1.91B | 2.35B | 2.41B | 2.35B |
| Operating Income | 886M | 1.51B | 891M | 1.08B | 1.08B | 212M | 144M | -883M | 382M | 577M | 621M |
| EBITDA | 1.02B | 1.69B | 1.07B | 1.22B | 1.19B | 454M | 379M | 254M | 643M | 826M | 497M |
| Net Income | 705M | 1.31B | 737M | 903M | 968M | 278M | 191M | -551M | 386M | 402M | 396M |
| EPS | 0.64 | 1.15 | 0.61 | 0.74 | 0.79 | 0.23 | 0.15 | -0.45 | 0.32 | 0.33 | 0.33 |
| Balance Sheet | |||||||||||
| Total Assets | 6.98B | 8.77B | 9.77B | 11.1B | 11.7B | 12.2B | 12.5B | 11.5B | 12.3B | 12.8B | 13.2B |
| Total Liabilities | 3.08B | 1.99B | 2.89B | 3.24B | 2.99B | 3.39B | 3.40B | 3.24B | 3.86B | 4.13B | 4.49B |
| Shareholders' Equity | 3.52B | 6.47B | 6.62B | 7.50B | 8.43B | 8.54B | 8.81B | 8.28B | 8.52B | 8.83B | 8.89B |
| Cash & Short-term Investments | 927M | 1.99B | 1.76B | 1.56B | 1.37B | 1.78B | 1.24B | 773M | 889M | 733M | 1.02B |
| Total Debt | 1.40B | 878M | 1.34B | 1.87B | 1.71B | 1.83B | 1.59B | 1.47B | 1.74B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 856M | 1.13B | 1.17B | 937M | 1.11B | 301M | 472M | 349M | 641M | 458M | - |
| Capital Expenditure | 288M | 486M | 729M | 866M | 716M | 572M | 542M | 504M | 628M | 559M | 623M |
| Free Cash Flow | 568M | 647M | 442M | 71.2M | 393M | -271M | -70.2M | -156M | 12.6M | -101M | -44.4M |
| Ratios | |||||||||||
| ROE | 20.0% | 20.2% | 11.1% | 12.0% | 11.5% | 3.3% | 2.2% | -6.7% | 4.5% | 4.6% | 4.5% |
| ROA | 10.1% | 14.9% | 7.5% | 8.2% | 8.3% | 2.3% | 1.5% | -4.8% | 3.1% | 3.1% | 3.0% |
| Net Profit Margin | 20.1% | 29.8% | 15.9% | 17.4% | 17.9% | 6.3% | 5.0% | -13.5% | 7.5% | 7.8% | 8.0% |
| Debt to Equity | 0.40x | 0.14x | 0.20x | 0.25x | 0.20x | 0.21x | 0.18x | 0.18x | 0.20x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Yifan Xinfu Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.51%
- Forward dividend
- 0.10 CNY
- Payout ratio
- 42.7%
- Ex-dividend date
- May 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 172M | 0.14 | 42.7% |
| 2024 | CNY 195M | 0.16 | 50.5% |
| 2023 | CNY 72.5M | 0.06 | - |
| 2022 | CNY 86.4M | 0.07 | 45.2% |
| 2021 | CNY 138M | 0.11 | 49.7% |
| 2020 | CNY 202M | 0.16 | 20.9% |
| 2019 | CNY 121M | 0.10 | 13.4% |
| 2018 | CNY 543M | 0.45 | 73.7% |
| 2017 | CNY 176M | 0.16 | 13.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 25:10 on May 16, 2016.
Who owns Yifan Xinfu Pharmaceutical Co Ltd
- Insiders 43.21%
- Institutions 5.40%
- Public & others 51.39%
- Shares outstanding 1.22B
- Free float 504M
Yifan Xinfu Pharmaceutical Co Ltd company profile
- Company name
- Yifan Xinfu Pharmaceutical Co Ltd
- Ticker
- 002019.SHE
- ISIN
- CNE000001K65
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jun 28, 2004
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,182
- Fiscal year end
- December
- Address
- No. 50, Qinshan, Hangzhou, China, 311300
- Phone
- 86 40 0180 2019
- Website
- yifanyy.com
About Yifan Xinfu Pharmaceutical Co Ltd
Yifan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products, vitamins, and polymer materials in China, South Korea, the Philippines, Vietnam, Italy, Thailand, and internationally. It offers pharmaceutical products, such as biopharmaceuticals, chemical drugs, and traditional Chinese medicines; vitamin products, including vitamin B5 and provitamin B5; and active pharmaceutical ingredients. The company was formerly known as Yifan Xinfu Pharmaceutical Co., Ltd. and changed its name to Yifan Pharmaceutical Co., Ltd. in October 2016. Yifan Pharmaceutical Co., Ltd. was founded in 2000 and is headquartered in Hangzhou, China.
Yifan Xinfu Pharmaceutical Co Ltd management
9- Mr. Xian Feng ChengChairman of the Board of Directors, President & GM · born 1968
- Mr. Dawei ZhangVP & CFO · born 1981
- Mr. Feng WangExecutive President · born 1973
- Ms. Li Ping QianExecutive President · born 1983
- Mr. Deqi FengBoard Secretary, Deputy GM, VP & Director · born 1979
- Mr. Ximing LiDeputy GM & VP · born 1961
- Ms. Yuhong GengDeputy GM & VP · born 1971
- Kai WangHead of Accounting
- Mr. William TanDirector of Sales Team